Skip to main content
S&P 5007,772.18-0.60%DOW50,992.80-1.03%NASDAQ27,400.23-0.72%BTC$83,189.00-3.49%ETH$2,567.06-5.34%GOLD$4,125.30-1.48%OIL$90.21+0.86%
Smart Investors Daily
SID Premium
EL

NASDAQ · ELTX

Elicio Therapeutics, Inc.

Healthcare · Biotechnology

$1.88

Up+$0.01 (+0.53%)

Updated Oct 7, 2026, 2:14 PM

SID Score

2.8/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
144.37M
P/E ratio
-3.04
Dividend yield
0.00%
52-week range
$1.71 – $16.00
Volume
259.1K
Avg. volume
97.45K

Price performance · ELTX

ELTX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 6, 2026

ELTX closed at $1.88 after 21 trading sessions, down 20.00% for the selected period.

Last close
$1.88
Period change
-20.00%
Period low
$1.77
Period high
$2.35
Daily close
View OHLC price history
ELTX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 6, 2026$1.90$1.96$1.86$1.88259.1K
Oct 5, 2026$1.93$1.96$1.81$1.92202.85K
Oct 2, 2026$1.95$1.97$1.85$1.92175.96K
Oct 1, 2026$1.82$1.9599$1.82$1.92311.26K
Sep 30, 2026$1.86$1.86$1.78$1.82274.03K
Sep 29, 2026$1.85$1.90$1.77$1.84452.47K
Sep 28, 2026$1.85$1.90$1.81$1.85222.07K
Sep 25, 2026$1.88$1.90$1.82$1.84165.36K
Sep 24, 2026$1.88$2.00$1.81$1.88339.77K
Sep 23, 2026$1.87$1.895$1.84$1.87195.35K
Sep 22, 2026$1.92$1.925$1.82$1.87404.04K
Sep 21, 2026$1.92$2.02$1.91$1.91484.46K
Sep 18, 2026$1.86$2.00$1.86$1.89689.74K
Sep 17, 2026$1.79$1.90$1.785$1.865340.17K
Sep 16, 2026$1.90$1.90$1.705$1.77629.87K
Sep 15, 2026$2.01$2.02$1.915$1.99319.02K
Sep 14, 2026$2.06$2.0899$1.95$2.00391.83K
Sep 11, 2026$2.14$2.20$2.02$2.05445.8K
Sep 10, 2026$2.17$2.20$2.07$2.11343.24K
Sep 9, 2026$2.37$2.375$2.17$2.18459.08K
Sep 8, 2026$2.42$2.46$2.34$2.35324.72K

Latest ELTX news

The latest Smart Investors Daily articles mentioning ELTX.

Stock researchCompany · Overview

ELTX research

Overview

Company profile and research snapshot.

Company profile

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$1.50
Implied upside
—
Analysts
—
ELTX recent ratings
DateFirmRatingTarget
Sep 24, 2026B. Riley SecuritiesBuy—
Aug 18, 2026HC Wainwright & Co.Buy—
Jun 16, 2026Jones TradingHold—
Jun 15, 2026HC Wainwright & Co.Buy—
Jun 10, 2026B. Riley SecuritiesBuy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 24, 2026

Elicio Therapeutics Announces Late-Breaking Phase 2 AMPLIFY-7P Data Selected for Proffered Paper Oral Presentation at ESMO Congress 2026

New pre-specified analyses from the randomized Phase 2 study will further characterize the clinical potential of ELI-002 7P (camupepimut) in adjuvant pancreatic cancerFindings are expected to inform a refined Phase 3 development strategy BOSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that new pre-specified ana

Yahoo · Aug 31, 2026

Elicio Therapeutics to Participate at the H.C. Wainwright 28th Annual Global Investment Conference

BOSTON, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX, “Elicio” or the “Company”), a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers, today announced that Robert Connelly, Chief Executive Officer and Pete DeMuth, PhD, Chief Scientific Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 28th Annual Global Investment Conference, taking place September 14-16, 2026, in New York, New York. H.C

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By